CLINICAL_TRIALS ClinicalTrials.gov record update

A Clinical Study Using Autologous T Cell Engineered With Chimeric Antigen Receptor Targeting to CD19（Cluster of Differentiation Antigen 19) in Treating Patients With Recurrent /Refractory B Cell Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02644655
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:02.107925+00:00
Published At: 2016-01-01T00:00:00+00:00
Record Updated At: 2016-01-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent B-Cell Tumor", "Refractory B-Cell Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-01-01"
protocolSection.identificationModule.nctId: "NCT02644655"
protocolSection.identificationModule.officialTitle: "A Clinical Study Using Autologous T Cell Engineered With Chimeric Antigen Receptor Targeting to CD19\uff08Cluster of Differentiation Antigen 19) in Treating Patients With Recurrent /Refractory B Cell Leukemia"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.